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Abstract: The prevalence of a variety of neglected diseases is an increasing serious public health problem in developing 
countries, particularly in the poorest and most remote areas with very little or no access to medical care. The 
consequences in terms of morbidity and mortality due to these infections are devastating and have a major social and 
economic impact in several relevant aspects. According to the World Health Organization, these diseases are one of the 
most important scientific and technological challenges that face humankind in the 21st century. Although they affect 
more than a billion people around the world, there are only a few safe and effective drugs currently available. The urgent 
need for new drugs has led pharmaceutical and academic R&D centers to employ more knowledge-based platforms, as 
an unprecedented opportunity to make a significant impact on the lives of disadvantaged people through the discovery of 
novel therapeutic options. In this perspective we discuss the successful application of modern medicinal chemistry 
approaches to neglected diseases. 
Keywords: Neglected diseases, Drug design, Virtual screening, Molecular dynamics, QSAR, Molecular modeling, 
Pharmacophore, LBDD, SBDD, Inhibitor. 
NEGLECTED DISEASES 
According to the World Health Organization (WHO), 
neglected tropical diseases (NTDs) are a 
heterogeneous group of 17 infectious conditions, which 
have as common attributes the prevalence in tropical 
areas of the globe, primarily striking developing 
countries, where the poorest population is the main 
target [1]. Approximately 150 countries are endemic in 
one of them, and a considerable fraction of 70% is 
plagued by two or more NTDs [1, 2]. In this group are 
included diseases such as Chagas' disease, dengue, 
human African trypanosomiasis (HAT), 
schistosomiasis, leishmaniasis, leprosy and lymphatic 
filariasis. Although NTDs affect approximately one and 
a half billion people around the world, the burden they 
cause are mostly concentrated in rural areas and 
degraded urban zones. Precarious habitations, water 
pollution, poor sanitary infrastructure and the 
consequent proliferation of vector insects are among 
the top causes of high concentration of NTDs in these 
environments [3]. In recent years, this general 
tendency has been changing because of the migration 
of an increasing number of cases to developed 
countries, mainly in North America, Europe and Asia. In 
addition to the group of NTDs defined by WHO, a 
broader terminology can be employed to define the 
array of neglected diseases (NDs), which includes  
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other deadly infectious conditions that generally receive 
relatively greater pharmaceutical interest and research 
funding, such as tuberculosis and malaria [4]. A report 
from the International Federation of Pharmaceutical 
Manufacturers & Associations (IFPMA), published in 
2012, revealed a 40% increase of R&D projects on 
NDs, when compared with 2011 [1, 5]. However, 
considering the 336 new chemical entities (NCEs) 
approved during the last decade, only four are 
indicated to NDs, three for malaria and one for 
diarrhoeal disease [4]. 
The treatments for NDs are extremely limited and 
often ineffective. Several drugs currently available were 
developed to treat other conditions, such as cancer, 
bacterial and viral infections [6]. Examples include the 
compounds eflornithine and miltefosine, initially 
developed for cancer therapy, but presently used in the 
treatment of HAT and leishmaniasis, respectively 
(Figure 1). Another example is nifurtimox, a drug used 
to treat Chagas' disease. Combination therapy with 
eflornithine and nifurtimox was found to be more safe 
and effective than treatment with eflornithine alone, and 
it has been recommended as first-line treatment for 
second-stage HAT. Melarsoprol, a drug formerly used 
in the treatment of late-stage HAT (Figure 1), is highly 
toxic to humans, a life-threatening characteristic of 
many antiprotozoal drugs. Another example is 
nifurtimox, whose gastrointestinal and neurological side 
effects have limited its therapeutic indication. In the 
past, nifurtimox was also used to treat HAT in 
combination with melarsoprol. Based on the present 
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situation and the serious existent problems, there is an 
urgent need for the development of new, effective and 
safe drugs for NDs [7, 8]. 
The research and development (R&D) trends for 
NDs have been changing because of the growing 
awareness on the subject in all levels of society, 
including governments, general public and the scientific 
community. As a consequence, the investments on 
basic and applied research have increased, mainly 
through public-private partnerships [9]. These 
multilateral efforts are generally coordinated and 
implemented by non-profit organizations in association 
with private companies and public research institutions. 
The Drugs for Neglected Diseases Initiative (DNDi); the 
Special Programme for Research and Training in 
Tropical Diseases (TDR) of WHO, and the Medicines 
for Malaria Venture (MMV) are involved in several 
projects in partnership with major pharmaceutical 
companies, such as Pfizer, GlaxoSmithKline, Novartis, 
AstraZeneca, Johnson & Johnson, Sanofi-Aventis, and 
others [9, 10]. These collaborations connecting private, 
public and government partners, include countries in all 
continents of world [6]. 
MEDICINAL CHEMISTRY AND DRUG DISCOVERY 
Historically, the drug R&D process was based on 
empirical strategies, such as the systematic screening 
of large collections of compounds on different 
experimental models, and the synthesis of derivatives 
of known active compounds [11]. More recently, a new 
paradigm has emerged in academic and industrial 
environments because of the lack of innovation and the 
limited investigation of the chemical and biological 
space imposed by the traditional models [12]. For this 
reason, an increasing use of highly integrated drug 
discovery approaches has been noted, involving a 
combination of experimental and computational 
methods [13]. 
Among the core technologies employed in the early 
identification of novel small molecule hits are the high 
throughput screening (HTS) and virtual screening (VS) 
methods (Figure 2) [14, 15]. HTS relies on the use of 
miniaturized and automated assays – binding, 
competition and enzymatic assays – upon a collection 
of generally hundreds of thousands of structurally 
diverse molecules. The output of the experiments 
consists of a large set of molecules that holds low to 
moderate binding affinity for the target, and that may be 
suitable to structural modification. Consequently, hit-to-
lead optimization efforts are undertaken to produce 
molecules with improved properties (e.g. potency, 
affinity, and selectivity) [16]. 
After the selection of lead compounds, the next step 
comprises the process of lead optimization (LO). At the 
optimization stage, structure- (SBDD) and ligand-based 
drug design (LBDD) methods are performed to improve 
the pharmacodynamics, pharmacokinetics and safety 
of the leads [17, 18]. The understanding of such a 
broad range of parameters is essential to provide the 
right balance in the characterization of the most 
promising compounds for further investigation [19]. 
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Figure 1: Structures of drugs used in the treatment of NDs. (1) Eflornithine; (2) Miltefosine; (3) Nifurtimox and (4) Melarsoprol. 
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The drug discovery process has been boosted, 
among other technological developments, by advances 
in combinatorial chemistry [20]. This approach provided 
the synthetic chemists the ability to generate large 
collections of compounds by exploring a small number 
of starting points in all allowed combinations through a 
given reaction sequence. From a medicinal chemist's 
point of view, combinatorial chemistry became an 
important tool in the organization of libraries of 
compounds for biological screening and hit 
identification [21]. 
On one hand, SBDD approaches rely on the use of 
3D structural data derived from a variety of molecular 
targets [22]. VS, molecular docking and molecular 
dynamics (MD) are among some of the most important 
methods [23, 24], where the main goal is to simulate 
the interaction between small-molecule ligands and 
biological targets to gather insights into critical 
intermolecular events [25]. On the other hand, LBDD 
methods focus on the investigation of known 
biologically active ligands to produce knowledge that 
can be applied in multiple ways in the design of new 
compounds [26, 27]. Pharmacophores, quantitative 
structure-activity relationships (QSAR) and ligand-
based VS (LBVS) are strategies usually employed in 
LBDD studies, both in academia and industry [28-30]. 
In addition, current data point out that the integration of 
SBDD and LBDD provides invaluable insights in lead 
identification and optimization, which are essential 
aspects of the drug discovery process [30-32]. 
STRUCTURE-BASED DRUG DESIGN STRATEGIES 
The phase of target identification and validation is 
an important basis of successful drug development in 
key areas of human health [33]. Technological 
advances in protein crystallography and nuclear 
magnetic resonance (NMR) have allowed the 
resolution of more than 80,000 proteins [34]. The vast 
availability of structural information for an increasing 
number of proteins has strongly contributed to the field 
of SBDD in modern drug discovery. This knowledge is 
broadly used in the area of NDs research for the design 
of high-affinity small-molecule ligands [23, 28, 35]. 
Figure 3 illustrates four crystal structures of 
extensively explored molecular targets for NTDs. 
These enzymes from the pathogens Schistosoma 
mansoni (3A), Trypanosoma cruzi (3B), Trypanosoma 
brucei (3C) and Leishmania (3D) are vital for the 
survival and proliferation of the parasites. The binding 
modes depicted in Figure 3 reveal the essential 
intermolecular interactions present in the complexes 
between proteins and small-molecule inhibitors. 
SBDD methods can be applied to the solution of 
several drug design problems, generally starting with 
the investigation of a 3D structure of a given biological 
target. Next, the appropriate binding cavity of the 
protein may be considered in the processes of ligand 
optimization or in silico screening of new ligands. 
Subsequently, a privileged set of compounds is either 
synthesized or purchased, and then experimentally 
tested in vitro against the target protein (Figure 4) [31]. 
Virtual Screening and Molecular Docking 
The in silico screening of libraries of compounds is 
one of most applied strategies to identify hits in the 
early phases of the drug discovery process. VS is the 
 
Figure 2: Key steps of the drug discovery and development process. NCE discovery: the achievement of a new chemical that 
has the attributes to proceed into the development phase and does not contain an active moiety that already has been approved 
by the regulatory agencies. Drug development: the process by which a drug candidate goes through extensive investigations in 
humans in order to prove its effectiveness and safety before its approval by the regulatory agencies. 
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Figure 3: Crystallographic structures of enzyme-inhibitor complexes. (A) Schistosoma mansoni purine nucleoside 
phosphorylase (PNP) in complex with a nucleoside analog (PDB ID: 3DJF); (B) Cruzain from Trypanosoma cruzi in complex with 
a bromophenoxy-acetamide inhibitor (PDB ID: 3KKU); (C) Trypanosoma brucei dihydrofolate reductase (DHFR) in complex with 
the inhibitor pyrimethamine (PDB ID: 3QFX); (D) Leishmania major pteridine reductase 1 with a 2,4-diaminopteridine inhibitor 
(PDB ID: 3H4V). Protein structures in cartoon, inhibitors in stick and water molecules in red spheres. 
 
 
Figure 4: SBDD in drug design. 
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Figure 5: Outline of a SBVS process. Among the several phases comprising the VS process, the filtering step is important to 
reduce de size of the database, and to restrict the chemical space being explored in terms of lead- or drug-like properties. 
ADME: absorption, distribution, metabolism and excretion. 
computational counterpart of the experimental 
screening (HTS). Basically, VS can be categorized into 
structure-based virtual screening (SBVS) and LBVS 
[36]. 
SBVS methods involve the computational docking 
of large libraries of small-molecule compounds into the 
binding site of the target protein [37]. Molecular docking 
is a well-known method used to predict the binding 
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conformation of the ligands within the binding pocket of 
the biological receptor [38]. It has been largely 
employed to evaluate the bound conformation 
preference and the free binding energy [39]. Binding 
conformations predicted by molecular docking are in 
general close to the corresponding binding 
conformations observed in crystallographic structures 
[38]. However, the difficulty to find correct binding 
solutions increases proportionally with the degree of 
flexibility of the docked molecules. In addition, the 
docking algorithms are applied to classify the 
compounds using a variety of scoring functions. The 
majority of the currently employed scoring functions is 
based on force fields, empirical data and knowledge of 
the protein-ligand interactions in order to predict the 
free energy of binding between the docked ligands and 
the macromolecular target [38, 39]. The ranking list is 
ultimately used to select a subset of promising 
compounds for experimental (in vitro) evaluation 
(Figure 5) [40]. 
Molecular Dynamics 
The selection of promising lead compounds 
requires the integration of different strategies. In this 
framework, SBVS can be combined with molecular 
dynamics (MD) simulations, considering that numerous 
molecular targets may undergo conformational 
changes of varied extensions. MD simulations play an 
essential role in the characterization of molecular 
motion [41]. In some cases, the receptor’s changes are 
small and the ligand fits into a well-defined cavity. In 
contrast, some proteins may undergo major alterations 
in their structure during the process of molecular 
recognition [42]. In the latter case, it is useful to 
generate an ensemble of structures, and then consider 
the most representative conformational states to 
produce meaningful SBVS results [43, 44]. 
MD simulations have been successfully employed in 
the elucidation of the molecular basis underlying 
experimental data, for instance, in the case of enzyme 
inhibition measurements [43, 45]. Regardless of some 
important limitations, such as the high computational 
cost and system size, MD has contributed in several 
ways in drug design projects, mainly when combined 
with other medicinal chemistry approaches [46]. 
LIGAND-BASED DRUG DESIGN STRATEGIES 
In a considerable number of cases, the discovery of 
new compounds with pharmacological activity can be 
done without the use of the target’s structural 
information. LBDD strategies are widely applied to the 
design and optimization of ligands based on the 
properties extracted from previously known active 
molecules (Figure 6) [47]. 
Pharmacophore modeling is one of the most 
important LBDD strategies employed in drug design 
[48]. This technology captures common structural 
features from a specific set of ligands, which are 
thought to be essential in the process of molecular 
binding to the target protein. Firstly, the conformational 
space for each molecule is delineated to characterize 
the conformations of the entire set of ligands [49]. Next, 
the several ligands are aligned and the key common 
features are identified. This results in the generation of 
a so called 3D pharmacophore hypothesis, which can 
then be used to search large databases of compounds 
with unknown activities [48, 49]. 
Another well-known LBDD method is quantitative 
structure-activity relationships (QSARs) [50]. Over the 
last decades QSAR models have been successfully 
used to describe and quantify the underlying 
correlations between molecular properties and 
biological activity [29, 50]. These relationships are 
converted to mathematical models that can be used to 
predict the biological activity of novel compounds not 
yet synthesized. According to the type of descriptor, 
QSAR methods can be broadly classified as 1D, 2D or 
3D. Several types of molecular descriptors can be 
employed: physicochemical (e.g. logP and pKa; 1D 
QSAR), topological and fingerprints (2D QSAR), and 
molecular interaction fields (3D QSAR) [51]. QSAR 
studies are usually applied to a specific chemical space 
to be explored in the design of new molecules with 
improved properties, particularly in the hit-to-lead and 
lead optimization phases [52, 53]. 
LBVS methods do not consider the 3D structure of 
the macromolecular target. In this case, the molecular 
properties of active compounds are used as the search 
criteria to identify molecules with similar structure. The 
search can be based on 1D, 2D or 3D molecular 
descriptors. The selection of adequate descriptors is 
critical, and depends on the nature of the molecules 
used as search templates. Typically used descriptors 
include 1D bit strings, 2D common substructures, and 
3D pharmacophore hypothesis and molecular shape 
[54, 55]. LBVS approaches are broadly divided in 
filtering or activity-based methods (Figure 7). By using 
filtering methods, large databases can be rapidly 
screened for molecules containing specific properties 
(e.g. lead-like, drug-like) or substructures, or absence 
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of toxic or undesired groups. In activity-based methods, 
QSAR models, pharmacophore hypothesis and 
classification models can be used to screen libraries of 
compounds, as well as to classify them as actives or 
inactives, and predict their activity [56]. 
The integration between LBDD and SBDD 
approaches is present in a vast number of cases 
described in the literature [57]. The use of these 
strategies requires a careful design to ensure 
maximum benefit [57]. In the following section we 
briefly discuss some examples of studies in the area of 
NDs.  
CURRENT MEDICINAL CHEMISTRY APPROACHES 
IN NEGLECTED DISEASES 
Valuable strategies in medicinal chemistry have 
been employed to the discovery and optimization of 
lead compounds for NDs. A few successful examples 
of the integration of VS, QSAR, molecular docking, 
pharmacophore modeling and MD are described 
below. 
Recently, a series of compounds exhibiting potent 
activity against Plasmodium falciparum was discovered 
[58]. The authors initially developed several QSAR 
models based on the in vitro activity of nearly 3,000 
 
Figure 6: LBDD strategies in medicinal chemistry. 
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compounds against P. falciparum cells. Subsequently, 
the ZINC database was filtered for drug-likeness 
properties. Next, the compounds selected were 
submitted to a procedure (applicability domain – AD – 
analysis) that delimitates the chemical space in which a 
QSAR model provides reliable predictions for both 
internal and external validation sets. Predictions were 
provided by QSAR models for the compounds within 
the AD, and a subset of promising compounds was 
experimentally tested. Several hits were found to inhibit 
the parasite’s growth in cell cultures. The interesting 
chemical diversity of the series can be further explored 
in the design of novel antimalarial agents (Figure 8A). 
The enzyme 2-trans-enoyl-ACP-CoA-reductase 
(InhA) is a key target of the fatty acid synthesis 
pathway of Mycobacterium tuberculosis, the causative 
agent of tuberculosis. A subset of the ZINC database 
was used in a strategy combining VS and 3D 
pharmacophore modeling [59]. Firstly, a 3D 
pharmacophore model was generated based on 
available InhA crystal structures. The information 
derived from SBDD and LBDD investigations allowed 
the generation of a pharmacophore consisting of four 
key points, which guided the selection of molecules 
with complementary properties to the InhA binding site. 
Subsequently, four docking programs were employed 
to compare the binding mode of the previously selected 
molecules. Three molecules possessing IC50 values 
ranging from 24 to 83 μM were identified. The study 
resulted in the discovery of promising novel scaffolds – 
oxadiazols and thiadiazols – as inhibitors of M. 
tuberculosis InhA (Figure 8B). 
In an interesting work, a combined strategy 
comprising docking studies and a HTS assay of 
approximately 20,000 compounds was developed 
employing the enzyme cruzain from T. cruzi, a 
validated target for Chagas' disease [60]. An initial set 
with nearly 1,000 hits was identified from the HTS 
campaign. Molecular docking studies were performed 
upon these hits, and the top scoring compounds were 
evaluated against the target enzyme. This procedure 
allowed the selection of a subset of potent inhibitors 
with Ki (the dissociation constant for the enzyme-
inhibitor complex) values in the low micromolar and 
nanomolar range (Figure 8C). These inhibitors, 
belonging to five different structural classes, are 
attractive starting points for future development. 
The association of protein crystallography and 
molecular docking led to the study of a series of potent 
inhibitors of the enzyme purine nucleoside 
phosphorylase (PNP) from Schistosoma mansoni, the 
causative agent of schistosomiasis [61]. 
Crystallographic data of the enzyme were used to 
assist the SBDD investigation of a series of 
deazaguanine derivatives and other purine bases. The 
compounds showed excellent inhibitory profile, with 
IC50 values in the nanomolar range (Figure 9A). The 
 
Figure 7: LBVS approaches. 
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authors also performed kinetic evaluations upon the 
human PNP to assess the selectivity of the inhibitors. 
Three compounds showed good selectivity towards the 
parasite’s enzyme. The obtained crystallographic 
complex for one of the inhibitors (Figure 3A) revealed 
several key structural features for selectivity that can 
be explored in the optimization of this series of 
inhibitors of S. mansoni PNP. 
The RNA-editing ligase (REL1) is an essential 
enzyme of the RNA editing pathway, a unique process 
of protozoa, which include the parasite Trypanosoma 
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Figure 9: (A) Structures of S. mansoni PNP deazaguanine inhibitors; (B) Structures of T. brucei REL1 inhibitors. 
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brucei, the causative agent of HAT. Drug-like inhibitors 
were discovered through the combination of MD and 
SBVS approaches [62]. A subset of the National 
Cancer Institute (NCI) database was virtually screened 
using a crystal structure of the enzyme (PDB ID: 
1XDN). The top scoring compounds were redocked 
into the binding pocket using structures of the enzyme 
obtained through MD – a process called relaxed 
complex scheme (RCS). Following this, the most 
promising compounds were filtered for drug-likeness, 
leading to the identification of potent inhibitors. The 
structure of the most potent inhibitor was used in a 
similarity search for new REL1 inhibitors, employing the 
entire NCI database (Figure 9B). This series of 
disulfonic acid derivatives are lead candidates for the 
development of new anti-HAT agents. 
CONCLUSIONS 
Although NDs account for 12% of the global health 
burden, only about 1% of the new NCEs launched over 
the last decade were targeted to these conditions [4]. 
To address this critical gap, pharmaceutical 
companies, not-for-profit organizations, academic and 
research institutions have been progressively more 
engaged in several modalities of partnerships to raise 
the levels of investments and research activities in the 
area of NDs. As a consequence, good opportunities 
are becoming increasingly available for these alarming 
public health problems. Current research has taken 
advantage of the existing open databases of small-
molecules and macromolecular targets, whose 
availability is likely to increase over the next years. This 
aspect is of great importance, particularly for the 
application of SBDD and LBDD methods. Successful 
examples of the use of these approaches can be found 
for a variety of different diseases and drug discovery 
programs. It seems clear that, from a careful 
examination of these cases, important information can 
emerge to support knowledge-based decisions. In this 
context, we believe that the use of a diversity of 
strategies in medicinal chemistry will continue to play a 
significant role in the area of NDs for the foreseeable 
future. 
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